FR2646438B1
(fr)
|
1989-03-20 |
2007-11-02 |
Pasteur Institut |
Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
|
US7144731B2
(en)
*
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
GEP20002145B
(en)
*
|
1989-10-16 |
2000-06-25 |
Amgen Inc Us |
Stem Cell Factor
|
US5733761A
(en)
*
|
1991-11-05 |
1998-03-31 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US5981730A
(en)
*
|
1994-04-13 |
1999-11-09 |
The General Hospital Corporation |
RPS gene family, primers, probes, and detection methods
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
WO1998007858A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Chiron Corporation |
HUMAN POLYHOMEOTIC 1(hphl) ACTS AS A TUMOR SUPPRESSOR
|
US5958727A
(en)
*
|
1996-09-13 |
1999-09-28 |
Novo Nordisk Biotech, Inc |
Methods for modifying the production of a polypeptide
|
RU2179034C2
(ru)
|
1996-09-13 |
2002-02-10 |
Транскариотик Терапиз, Инк. |
ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
|
CA2266752A1
(en)
|
1996-10-01 |
1998-04-09 |
Geron Corporation |
Telomerase reverse transcriptase
|
US6855545B1
(en)
|
1996-10-04 |
2005-02-15 |
Lexicon Genetics Inc. |
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
|
US7332338B2
(en)
|
1996-10-04 |
2008-02-19 |
Lexicon Pharmaceuticals, Inc. |
Vectors for making genomic modifications
|
US6136566A
(en)
*
|
1996-10-04 |
2000-10-24 |
Lexicon Graphics Incorporated |
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
|
US20040072243A1
(en)
*
|
1996-10-11 |
2004-04-15 |
Lexicon Genetics Incorporated |
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
|
ATE406176T1
(de)
|
1996-12-06 |
2008-09-15 |
Amgen Inc |
Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
|
AU5796298A
(en)
*
|
1996-12-11 |
1998-07-03 |
Chiron Corporation |
Secreted human proteins
|
US20020168718A1
(en)
*
|
1997-04-03 |
2002-11-14 |
California Institute Of Technology |
Enzyme-mediated modification of fibrin for tissue engineering
|
AU7381098A
(en)
|
1997-05-16 |
1998-12-08 |
Novo Nordisk Biotech, Inc. |
Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
|
US6639050B1
(en)
|
1997-07-21 |
2003-10-28 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
US7378506B2
(en)
*
|
1997-07-21 |
2008-05-27 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
TR200000140T2
(tr)
*
|
1997-07-23 |
2000-05-22 |
Roche Diagnostics Gmbh |
Endojenik gen etkinliği ile insan proteini üretimi için insan hücre sıralarının belirlenmesi
|
ES2255177T5
(es)
*
|
1997-07-23 |
2011-07-12 |
Roche Diagnostics Gmbh |
Fabricación de proteínas mutadas humanas en células humanas por medio de la recombinación homóloga.
|
PT986644E
(pt)
|
1997-07-23 |
2007-01-31 |
Roche Diagnostics Gmbh |
Preparação de eritropoietina por activação genética endógena com promotores virais
|
AU776280B2
(en)
*
|
1997-07-23 |
2004-09-02 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
CA2298015C
(en)
*
|
1997-07-23 |
2015-01-27 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
US6548296B1
(en)
|
1997-07-23 |
2003-04-15 |
Roche Diagnostics Gmbh |
Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
|
KR100622203B1
(ko)
*
|
1997-07-23 |
2006-09-07 |
로셰 디아그노스틱스 게엠베하 |
내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
|
DK1017803T3
(da)
*
|
1997-09-26 |
2010-08-23 |
Abt Holding Co |
Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
|
US7316923B1
(en)
|
1997-09-26 |
2008-01-08 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6897066B1
(en)
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
ZA989497B
(en)
*
|
1997-10-20 |
2000-04-19 |
Roche Diagnostics Gmbh |
Positive-negative selection in homologous recombination.
|
KR20010031713A
(ko)
|
1997-11-03 |
2001-04-16 |
벤슨 로버트 에이치. |
맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
|
JP4220125B2
(ja)
*
|
1997-12-03 |
2009-02-04 |
ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
高い比活性を有するエリスロポエチン
|
US7037663B2
(en)
*
|
1998-02-19 |
2006-05-02 |
Eastern Virginia Medical School |
Human zona pellucida protein 3 and uses thereof
|
ES2234274T3
(es)
|
1998-02-19 |
2005-06-16 |
Eastern Virginia Medical School |
Proteina 3 recombinante activa de la zona pelucida humana (hzp3).
|
AU3066699A
(en)
|
1998-03-03 |
1999-09-20 |
Johns Hopkins University, The |
Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6808921B1
(en)
*
|
1998-03-27 |
2004-10-26 |
Lexicon Genetics Incorporated |
Vectors for gene mutagenesis and gene discovery
|
US6436707B1
(en)
*
|
1998-03-27 |
2002-08-20 |
Lexicon Genetics Incorporated |
Vectors for gene mutagenesis and gene discovery
|
WO1999057263A1
(en)
*
|
1998-05-07 |
1999-11-11 |
Transkaryotic Therapies, Inc. |
Modifying the expression of the fsh beta gene by homologous recombination
|
US6242218B1
(en)
*
|
1998-05-07 |
2001-06-05 |
Transkaryotic Therapies Inc. |
Genomic sequences for protein production and delivery
|
EP1075531A1
(en)
*
|
1998-05-07 |
2001-02-14 |
Transkaryotic Therapies, Inc. |
Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery
|
CN1307642A
(zh)
*
|
1998-05-27 |
2001-08-08 |
诺沃诺尔迪斯克生物技术有限公司 |
通过改变基因拷贝数制备多肽的方法
|
CA2333852C
(en)
|
1998-07-21 |
2007-05-29 |
Cobra Therapeutics Limited |
A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
|
US7601685B2
(en)
*
|
1998-08-27 |
2009-10-13 |
Eidgenossische Technische Hochschule Zurich |
Growth factor modified protein matrices for tissue engineering
|
US7241730B2
(en)
|
1998-08-27 |
2007-07-10 |
Universitat Zurich |
Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
|
US6894022B1
(en)
|
1998-08-27 |
2005-05-17 |
Eidgenossische Technische Hochschule Zurich |
Growth factor modified protein matrices for tissue engineering
|
SE9803099D0
(sv)
|
1998-09-13 |
1998-09-13 |
Karolinska Innovations Ab |
Nucleic acid transfer
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
US6416975B1
(en)
|
1998-11-12 |
2002-07-09 |
Gliatech, Inc. |
Human glycine transporter type 2
|
EP1137773B1
(en)
|
1998-12-07 |
2008-08-13 |
ZymoGenetics, Inc. |
Growth factor homolog zvegf3
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
EP1155131B1
(en)
*
|
1999-02-19 |
2008-07-23 |
ABT Holding Company |
Vector comprising a splice acceptor trap and a poly a trap and the corresponding eukaryotic host cells
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
US6489308B1
(en)
|
1999-03-05 |
2002-12-03 |
Trustees Of University Of Technology Corporation |
Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
|
AU3864000A
(en)
*
|
1999-03-05 |
2000-09-21 |
Trustees Of University Technology Corporation, The |
Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
|
WO2000051624A2
(en)
*
|
1999-03-05 |
2000-09-08 |
The Trustees Of University Technology Corporation |
Methods and compositions useful in inhibiting apoptosis
|
US6849605B1
(en)
*
|
1999-03-05 |
2005-02-01 |
The Trustees Of University Technology Corporation |
Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
|
MXPA01009074A
(es)
|
1999-03-09 |
2002-03-27 |
Zymogenetics Inc |
Nuevo ligando zalfa11 de citocina.
|
CN100510096C
(zh)
|
1999-03-22 |
2009-07-08 |
诺沃奇梅兹有限公司 |
用于在真菌细胞中表达基因的启动子
|
JP2002541213A
(ja)
|
1999-04-13 |
2002-12-03 |
インヘール セラピューティック システムズ, インコーポレイテッド |
不妊症の処置のための乾燥粉末処方物の肺投与
|
CN1399681A
(zh)
*
|
1999-06-15 |
2003-02-26 |
基因特罗生物治疗公司 |
在细胞培养物中增强细胞因子产生的方法
|
EP1860188B1
(en)
|
1999-07-07 |
2011-05-04 |
ZymoGenetics, Inc. |
Human cytokine receptor
|
EP2275559A3
(en)
|
1999-09-28 |
2011-03-23 |
Shire Human Genetic Therapies, Inc. |
Optimized messenger RNA
|
AU783767B2
(en)
|
1999-10-14 |
2005-12-01 |
Takara Bio Usa, Inc. |
Anthozoa derived chromophores/fluorophores and methods for using the same
|
CA2391906A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Transkaryotic Therapies, Inc. |
Nucleic acid construct for optimized production of products
|
AU1925701A
(en)
|
1999-11-22 |
2001-06-04 |
Zymogenetics Inc. |
Method of forming a peptide-receptor complex with zsig33
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
WO2001042442A2
(en)
*
|
1999-12-10 |
2001-06-14 |
Cytos Biotechnology Ag |
Activation of endogenous genes by genomic introduction of a replicon
|
DE60043944D1
(de)
|
1999-12-23 |
2010-04-15 |
Zymogenetics Inc |
Zytokin zcyt018
|
ATE402258T1
(de)
|
2000-01-10 |
2008-08-15 |
Novartis Vaccines & Diagnostic |
Gene differentiell experimiert in brudtkrebs
|
TW201006846A
(en)
|
2000-03-07 |
2010-02-16 |
Senomyx Inc |
T1R taste receptor and genes encidung same
|
US6569681B1
(en)
*
|
2000-03-14 |
2003-05-27 |
Transkaryotic Therapies, Inc. |
Methods of improving homologous recombination
|
EP1728862A1
(en)
|
2000-03-16 |
2006-12-06 |
Genetica, Inc. |
Methods and compositions for RNA interference
|
US20030084471A1
(en)
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
EP1276756A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US20030195707A1
(en)
*
|
2000-05-25 |
2003-10-16 |
Schork Nicholas J |
Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US20020077775A1
(en)
*
|
2000-05-25 |
2002-06-20 |
Schork Nicholas J. |
Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
GB0018876D0
(en)
*
|
2000-08-01 |
2000-09-20 |
Applied Research Systems |
Method of producing polypeptides
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7138262B1
(en)
|
2000-08-18 |
2006-11-21 |
Shire Human Genetic Therapies, Inc. |
High mannose proteins and methods of making high mannose proteins
|
EP1349946B1
(en)
|
2000-08-25 |
2011-01-26 |
BASF Plant Science GmbH |
Plant polynucleotides encoding prenyl proteases
|
US20030129162A1
(en)
*
|
2000-09-12 |
2003-07-10 |
Lau Allan S. |
Compositions comprising mixtures of therapeutic proteins and methods of producing the same
|
EP1318834A2
(en)
*
|
2000-09-12 |
2003-06-18 |
Genetrol Biotherapeutics, Inc. |
Compositions comprising mixtures of human cytokines and methods of producing the same
|
US20020150541A1
(en)
*
|
2000-09-12 |
2002-10-17 |
Gene Trol Biotherapeutics, Inc. |
Compositions comprising mixtures of therapeutic proteins and methods of producing the same
|
US7381713B2
(en)
*
|
2000-12-04 |
2008-06-03 |
Sioan-Kettering Institute For Cancer Research |
Treatment of cancer by reduction of intracellular energy and pyrimidines
|
CA2436847A1
(en)
*
|
2000-12-04 |
2002-06-13 |
Sloan-Kettering Institute For Cancer Research |
Treatment of cancer by reduction of intracellular energy and pyrimidines
|
BR0116381A
(pt)
*
|
2000-12-20 |
2004-02-25 |
Hoffmann La Roche |
Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
|
WO2002049673A2
(en)
|
2000-12-20 |
2002-06-27 |
F. Hoffmann-La Roche Ag |
Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
|
TW201022287A
(en)
|
2001-01-03 |
2010-06-16 |
Senomyx Inc |
T1R taste receptors and genes encoding same
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
AU2002250032B2
(en)
|
2001-02-09 |
2008-06-05 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
CA2441071C
(en)
|
2001-03-14 |
2010-06-22 |
Myriad Genetics, Inc. |
Tsg101-gag interaction and use thereof
|
US7883856B2
(en)
|
2001-04-05 |
2011-02-08 |
Senomyx Inc. |
Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
|
WO2002081639A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081640A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
EP2228389B1
(en)
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antibodies against vascular endothelial growth factor 2
|
US7309783B2
(en)
*
|
2001-05-09 |
2007-12-18 |
The University Of Connecticut |
Mammalian early developmental regulator gene
|
WO2002091999A2
(en)
*
|
2001-05-09 |
2002-11-21 |
Geron Corporation |
Treatment for wounds
|
EP2003451B1
(en)
|
2001-06-26 |
2012-05-30 |
Senomyx, Inc. |
T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds
|
CA2452337A1
(en)
|
2001-07-10 |
2003-01-23 |
Senomyx, Inc. |
Use of specific t2r taste receptors to identify compounds that block bitter taste
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
CA2456821A1
(en)
*
|
2001-08-02 |
2003-02-13 |
Trinity Biomedical Technology Corporation |
Human zona pellucida proteins and methods of their use in diagnosing male infertility
|
WO2003014151A2
(en)
*
|
2001-08-10 |
2003-02-20 |
Genset S.A. |
Human secreted proteins, their encoding polynucleotides, and uses thereof
|
US20050064587A1
(en)
*
|
2001-09-07 |
2005-03-24 |
Lawrence Rosenberg |
Pancreatic small cells and uses thereof
|
WO2004039826A1
(en)
|
2001-11-14 |
2004-05-13 |
Centocor, Inc. |
Anti-il-6 antibodies, compositions, methods and uses
|
AU2002352119B2
(en)
*
|
2001-11-28 |
2008-01-03 |
Serono Genetics Institute S.A. |
Human cDNAs and proteins and uses thereof
|
US7247609B2
(en)
*
|
2001-12-18 |
2007-07-24 |
Universitat Zurich |
Growth factor modified protein matrices for tissue engineering
|
WO2003054158A2
(en)
*
|
2001-12-19 |
2003-07-03 |
The University Of Chicago |
Rapidly maturing fluorescent proteins and methods for using the same
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
EP2230299B1
(en)
|
2002-01-18 |
2011-12-07 |
ZymoGenetics, Inc. |
Novel cytokine ZCYTOR17 ligand
|
KR20040095217A
(ko)
|
2002-02-07 |
2004-11-12 |
델타 바이오테크놀로지 리미티드 |
알부민-융합 항-혈관신생 펩타이드
|
AU2003211128A1
(en)
|
2002-02-20 |
2003-09-09 |
American Integrated Biologics, Inc. |
Transgenic production in saliva
|
US20100151556A1
(en)
*
|
2002-03-15 |
2010-06-17 |
Cellectis |
Hybrid and single chain meganucleases and use thereof
|
US8206965B2
(en)
*
|
2002-03-15 |
2012-06-26 |
Cellectis S.A. |
Hybrid and single chain meganucleases and use thereof
|
WO2009095742A1
(en)
*
|
2008-01-31 |
2009-08-06 |
Cellectis |
New i-crei derived single-chain meganuclease and uses thereof
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US8148155B2
(en)
|
2002-04-22 |
2012-04-03 |
Novozymes, Inc. |
Methods for increasing homologous recombination of a nucleic acid sequence
|
WO2003090695A2
(en)
|
2002-04-25 |
2003-11-06 |
Transkaryotic Therapies, Inc. |
TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
WO2004009775A2
(en)
|
2002-07-19 |
2004-01-29 |
Targacept, Inc. |
Methods and compositions relating to chimeric nicotinic receptor subunits
|
US7459435B2
(en)
*
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
DK1585822T3
(da)
|
2002-11-18 |
2012-05-14 |
Novozymes Inc |
Promotorvarianter til ekspression af gener i en fungal celle
|
CN1829804A
(zh)
*
|
2002-11-22 |
2006-09-06 |
约翰斯·霍普金斯大学 |
治疗认知功能障碍的靶位
|
US7459436B2
(en)
*
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
CA2508375C
(en)
*
|
2002-12-02 |
2014-05-27 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
EP1570071A2
(en)
*
|
2002-12-10 |
2005-09-07 |
Ottawa Health Research Institute |
Modulation of stem cell differentiation by modulation of caspase-3 activity
|
US20050048041A1
(en)
*
|
2003-01-13 |
2005-03-03 |
Rao Mahendra S. |
Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
|
WO2004064785A2
(en)
|
2003-01-14 |
2004-08-05 |
Dana Farber Cancer Institute |
Cancer therapy sensitizer
|
WO2004065551A2
(en)
*
|
2003-01-21 |
2004-08-05 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
AU2004208030B2
(en)
|
2003-01-28 |
2009-05-07 |
Cellectis |
Custom-made meganuclease and use thereof
|
US8227212B2
(en)
|
2003-02-11 |
2012-07-24 |
Shire Human Genetic Therapies, Inc. |
Cell that expresses a sulfatase and a formylglycine generating enzyme
|
WO2004098634A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
Protein arginine n-methyltransferase 2 (prmt-2)
|
US20060252120A1
(en)
*
|
2003-05-09 |
2006-11-09 |
Kieliszewski Marcia J |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
US20050106222A1
(en)
*
|
2003-06-11 |
2005-05-19 |
Ailor Eric N. |
Method to increase protein production in culture
|
BRPI0413347A
(pt)
|
2003-08-06 |
2006-10-10 |
Senomyx Inc |
novos sabores, modificadores de sabor, agentes de sabor, realçadores de sabor, agentes de sabor e/ou realçadores umami ou doces, e utilização correspondente
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
JP2007507224A
(ja)
*
|
2003-09-30 |
2007-03-29 |
レキシコン ジェネティックス インコーポレーテッド |
遺伝子の機能を定義するための方法および組成物
|
EP1691852A2
(en)
*
|
2003-11-10 |
2006-08-23 |
Angiotech International AG |
Medical implants and fibrosis-inducing agents
|
ES2515818T3
(es)
|
2003-11-20 |
2014-10-30 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Células madre multipotentes postnatales de ligamento periodontal humano y sus usos
|
ES2380022T3
(es)
*
|
2003-12-03 |
2012-05-07 |
Monika KRÖZ |
Proteínas de fusión a interleucina-11
|
CN1901934B
(zh)
*
|
2003-12-19 |
2013-09-11 |
弗·哈夫曼-拉罗切有限公司 |
促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途
|
CA2553257A1
(en)
*
|
2004-01-14 |
2005-08-04 |
Ohio University |
Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
|
WO2005100387A1
(en)
*
|
2004-04-07 |
2005-10-27 |
The University Of Chicago |
Monomeric red fluorescent proteins
|
CA2573918A1
(en)
|
2004-04-19 |
2005-11-24 |
Ohio University |
Cross-linkable glycoproteins and methods of making the same
|
EP1774031A2
(en)
*
|
2004-05-26 |
2007-04-18 |
Wisconsin Alumni Research Foundation |
Cancer treatment method by inhibiting mage gene expression or function
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
CA2579677A1
(en)
*
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
MX2007007732A
(es)
*
|
2004-12-22 |
2007-10-08 |
Kuros Biosurgery Ag |
Hidrogeles peg con grupos funcionales para la reaccion de adicion tipo michael con biofactores incorporados con el factor xiiia.
|
EP2298887A1
(en)
|
2004-12-30 |
2011-03-23 |
Agency for Science, Technology and Research |
Chinese hamster apoptosis-related genes
|
US8575101B2
(en)
|
2005-01-06 |
2013-11-05 |
Kuros Biosurgery Ag |
Supplemented matrices for the repair of bone fractures
|
BRPI0606409A2
(pt)
*
|
2005-01-06 |
2009-06-23 |
Kuros Biosurgery Ag |
matrizes suplementadas para o reparo de fraturas ósseas
|
WO2006073711A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Kuros Biosurgery Ag |
Use of a matrix comprising a contrast agent in soft tissues
|
US20090104159A1
(en)
|
2005-02-10 |
2009-04-23 |
Felipe Prosper |
Vascular/Lymphatic Endothelial Cells
|
US20060194740A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Ulevitch Richard J |
NOD1 as an anti-tumor agent
|
US20060234973A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Kevin Fitzgerald |
Transcription factor RNA interference reagents and methods of use thereof
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
US20070011752A1
(en)
*
|
2005-05-06 |
2007-01-11 |
American Integrated Biologics, Inc. |
Production of human proteins in transgenic animal saliva
|
ATE515512T1
(de)
|
2005-05-12 |
2011-07-15 |
Zymogenetics Inc |
Zusammensetzungen und verfahren zur modulierung von immunreaktionen
|
AU2006265002B2
(en)
|
2005-06-30 |
2012-09-20 |
Centocor, Inc. |
Anti-IL-23 antibodies, compositions, methods and uses
|
EP1904652A2
(en)
*
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US20080242834A1
(en)
*
|
2005-07-08 |
2008-10-02 |
Ohio University |
Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
EP3031470A3
(en)
|
2005-09-09 |
2016-08-10 |
The Johns Hopkins University |
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
|
US20070072795A1
(en)
*
|
2005-09-28 |
2007-03-29 |
Anton Haselbeck |
Treatment of neurodegenerative disorders
|
AU2006344395B2
(en)
|
2005-10-13 |
2013-05-02 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
CN101605810B
(zh)
|
2005-10-20 |
2013-07-17 |
塞诺米克斯公司 |
嵌合的人甜味-鲜味和鲜味-甜味受体
|
WO2007060495A1
(en)
*
|
2005-10-25 |
2007-05-31 |
Cellectis |
I-crei homing endonuclease variants having novel cleavage specificity and use thereof
|
US7749704B2
(en)
|
2005-11-01 |
2010-07-06 |
Mayo Foundation For Medical Education And Research |
Promoter polymorphisms of the BLyS gene and use in diagnostic methods
|
KR20080072644A
(ko)
|
2005-11-03 |
2008-08-06 |
레드포인트 바이오 코포레이션 |
Trpm5 이온 채널용 고속 처리 스크리닝 검정
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
JP5364382B2
(ja)
|
2006-02-07 |
2013-12-11 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
遊離チオール部分を有するタンパク質の安定化された組成物
|
JP5386180B2
(ja)
|
2006-02-28 |
2014-01-15 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
真皮細胞のコンパクト凝集のための方法
|
LT2004683T
(lt)
*
|
2006-03-24 |
2016-10-10 |
Biogen Hemophilia Inc. |
Pc5, kaip faktoriaus ix pro-peptidą apdorojantis fermentas
|
EP3398452A3
(en)
|
2006-04-21 |
2018-11-28 |
Senomyx, Inc. |
Comestible compositions comprising high potency savory flavorants, and processes for producing them
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US7674594B2
(en)
|
2006-07-27 |
2010-03-09 |
Redpoint Bio Corporation |
Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol
|
JP5723528B2
(ja)
|
2006-08-04 |
2015-05-27 |
プロロング ファーマシューティカルズ エルエルシー |
修飾されたエリスロポエチン
|
JP5256199B2
(ja)
*
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
JP2008044926A
(ja)
*
|
2006-08-14 |
2008-02-28 |
Trustees Of Columbia Univ In The City Of New York |
Wnt信号伝達に関係した分泌タンパク質
|
EP2120998B1
(en)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
EP2136778A2
(en)
*
|
2007-03-20 |
2009-12-30 |
Harold Brem |
Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
|
EP2139447A2
(en)
*
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
DK2136850T3
(da)
*
|
2007-04-13 |
2012-04-10 |
Kuros Biosurgery Ag |
Polymervævforsegling
|
WO2008128227A1
(en)
|
2007-04-16 |
2008-10-23 |
Momenta Pharmaceuticals, Inc. |
Defined glycoprotein products and related methods
|
CL2008002053A1
(es)
*
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
|
CL2008002054A1
(es)
*
|
2007-07-17 |
2009-05-29 |
Hoffmann La Roche |
Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
JP2010534664A
(ja)
|
2007-07-23 |
2010-11-11 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
Il−17拮抗薬を用いた線維症関連疾患治療の方法及び組成物
|
CZ2010180A3
(cs)
|
2007-08-21 |
2010-10-13 |
Senomyx, Inc |
Identifikace lidských T2R receptoru, které reagují na horké slouceniny, které vyvolavají horkou chut v kompozicích, a jejich použití v testech pro identifikaci sloucenin, které inhibují (blokují) horkou chut v kompozicích a jejich použití
|
US8679749B2
(en)
*
|
2007-11-01 |
2014-03-25 |
The University Of Chicago |
Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
|
US8003325B2
(en)
*
|
2007-11-30 |
2011-08-23 |
Mayo Foundation For Medical Education And Research |
Polymorphisms of the BLyS gene and use in diagnostic methods
|
JP2012512812A
(ja)
*
|
2007-12-28 |
2012-06-07 |
クロス・バイオサージェリー・アクチェンゲゼルシャフト |
フィブリンフォームに組込まれたpdgf融合タンパク質
|
WO2009089380A2
(en)
*
|
2008-01-08 |
2009-07-16 |
The Trustees Of Columbia University In The City Of New York |
Methods for p2ry5 mediated regulation of hair growth and mutants thereof
|
US20110104133A1
(en)
|
2008-05-06 |
2011-05-05 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
MX2011004550A
(es)
|
2008-10-31 |
2011-07-20 |
Centocor Ortho Biotech Inc |
Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
|
JP5873335B2
(ja)
|
2009-02-12 |
2016-03-01 |
ヤンセン バイオテツク,インコーポレーテツド |
フィブロネクチンiii型ドメインに基づくスカフォールド組成物、方法及び使用
|
EP3488837A1
(en)
|
2009-07-15 |
2019-05-29 |
NewSouth Innovations Pty Limited |
Electroporation apparatus for providing agents to the cochlea
|
EP2459212B1
(en)
|
2009-07-28 |
2018-03-14 |
Shire Human Genetic Therapies, Inc. |
Compositions and methods for treating gaucher disease
|
KR20230164773A
(ko)
*
|
2009-08-28 |
2023-12-04 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
PE20130192A1
(es)
|
2010-03-30 |
2013-02-27 |
Centocor Ortho Biotech Inc |
Anticuerpos il-25 humanizados
|
PL2616101T3
(pl)
|
2010-09-14 |
2015-01-30 |
Hoffmann La Roche |
Sposób oczyszczania pegylowanej erytropoetyny
|
CN103370076A
(zh)
|
2010-11-02 |
2013-10-23 |
纽约市哥伦比亚大学托管会 |
治疗毛发脱落疾病的方法
|
DK2646558T3
(en)
|
2010-11-30 |
2016-10-03 |
Novozymes Inc |
Promoters for expression of genes in a fungal cell
|
WO2012075412A1
(en)
|
2010-12-03 |
2012-06-07 |
Michael Verneris |
Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
|
AU2011338504B2
(en)
|
2010-12-07 |
2015-01-22 |
Vnomics Corp. |
System and method for measuring and reducing vehicle fuel waste
|
US9284588B2
(en)
|
2010-12-16 |
2016-03-15 |
Novozymes, Inc. |
Promoters for expressing genes in a fungal cell
|
AU2011352205B2
(en)
|
2010-12-31 |
2016-06-16 |
Bioatla, Llc |
Express humanization of antibodies
|
WO2012101671A1
(en)
|
2011-01-25 |
2012-08-02 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human recombinant iduronate 2-sulfatase
|
CN103732628B
(zh)
|
2011-03-03 |
2017-06-23 |
酵活有限公司 |
多价杂多聚体骨架设计和构建体
|
EP2686027B1
(en)
|
2011-03-16 |
2021-05-05 |
Kuros Biosurgery AG |
Pharmaceutical formulation for use in spinal fusion
|
RU2495933C2
(ru)
*
|
2011-05-30 |
2013-10-20 |
Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") |
ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ РОДА Escherichia ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА (ТАП) ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ) ИЛИ [-1]МЕТИОНИЛ-ФРАГМЕНТ ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), СПОСОБ ПОЛУЧЕНИЯ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ)
|
WO2013013017A2
(en)
*
|
2011-07-21 |
2013-01-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
|
CN104519905A
(zh)
|
2012-03-02 |
2015-04-15 |
夏尔人类遗传性治疗公司 |
用于治疗iii型戈谢病的组合物和方法
|
WO2013177287A1
(en)
*
|
2012-05-22 |
2013-11-28 |
Georgia Regents University |
Methods and vectors for gene targeting with inducible specific expression
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
WO2014016873A1
(en)
|
2012-07-26 |
2014-01-30 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of recombinant human alpha-galactosidase a
|
CN103864913A
(zh)
|
2012-12-18 |
2014-06-18 |
联亚生技开发股份有限公司 |
重组蛋白
|
EP2958585A1
(en)
|
2013-02-22 |
2015-12-30 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2851086A1
(en)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpins: methods of therapeutic ß-cell regeneration and function
|
EP2769732A1
(en)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US10066001B2
(en)
|
2013-03-15 |
2018-09-04 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
EP3010582B1
(en)
|
2013-06-21 |
2021-04-28 |
Newsouth Innovations Pty Limited |
Method and apparatus for close-field electroporation
|
US10563225B2
(en)
*
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
CA2874083C
(en)
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
WO2016116966A1
(en)
|
2015-01-22 |
2016-07-28 |
Jcr Pharmaceuticals Co., Ltd. |
Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
CN108290948B
(zh)
|
2015-09-21 |
2021-10-29 |
伊拉兹马斯大学医疗中心 |
抗-cd47抗体及使用方法
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
US11594135B2
(en)
|
2015-11-02 |
2023-02-28 |
Memgen, Inc. |
Methods of CD40 activation and immune checkpoint blockade
|
BR112018069776A2
(pt)
|
2016-03-29 |
2019-02-05 |
Janssen Biotech Inc |
tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
|
MX2019000643A
(es)
|
2016-07-15 |
2019-06-13 |
Poseida Therapeutics Inc |
Receptores de antigenos quimericos y metodos de uso.
|
KR102470282B1
(ko)
|
2016-07-15 |
2022-11-24 |
에프. 호프만-라 로슈 아게 |
Peg화 에리트로포이에틴을 정제하기 위한 방법
|
AU2017296237A1
(en)
|
2016-07-15 |
2019-01-03 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
|
EP3519561A1
(en)
|
2016-09-30 |
2019-08-07 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
JP2020500152A
(ja)
|
2016-09-30 |
2020-01-09 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
|
IL265664B2
(en)
|
2016-10-06 |
2024-02-01 |
Poseida Therapeutics Inc |
Inducible caspases and methods of use
|
EP3541422A4
(en)
|
2016-11-16 |
2020-05-06 |
Janssen Biotech, Inc. |
METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
MA47362A
(fr)
|
2017-01-30 |
2019-12-04 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
|
MA47442A
(fr)
|
2017-02-07 |
2019-12-18 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
|
CA3056227A1
(en)
|
2017-03-13 |
2018-09-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
|
WO2019051424A2
(en)
|
2017-09-08 |
2019-03-14 |
Poseida Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US10329543B2
(en)
|
2017-10-23 |
2019-06-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory T cells, methods of making and methods of using same
|
TWI831759B
(zh)
|
2017-12-01 |
2024-02-11 |
美商思進公司 |
Cd47抗體及其用於治療癌症之用途
|
BR112020012555A2
(pt)
|
2017-12-20 |
2020-11-24 |
Poseida Therapeutics, Inc. |
composições de vcar e métodos para uso
|
JP7137625B2
(ja)
|
2017-12-29 |
2022-09-14 |
エフ.ホフマン-ラ ロシュ アーゲー |
Peg化タンパク質組成物を提供するための方法
|
JP7227633B2
(ja)
|
2017-12-29 |
2023-02-22 |
エフ. ホフマン-ラ ロシュ エージー. |
Peg化タンパク質組成物を提供するための方法
|
EP3731872B1
(en)
|
2017-12-29 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Process for providing pegylated protein composition
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
CA3092947A1
(en)
|
2018-03-07 |
2019-09-12 |
Poseida Therapeutics, Inc. |
Cartyrin compositions and methods for use
|
KR20210003825A
(ko)
|
2018-04-20 |
2021-01-12 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법에 있어서의 크로마토그래피 컬럼 적격성 평가
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
|
JP2021536249A
(ja)
|
2018-09-05 |
2021-12-27 |
ポセイダ セラピューティクス,インコーポレイティド |
同種異系細胞組成物およびその使用方法
|
JP7359845B2
(ja)
|
2018-09-24 |
2023-10-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
|
KR20210093973A
(ko)
|
2018-11-20 |
2021-07-28 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
EP3898993A1
(en)
|
2018-12-20 |
2021-10-27 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
EP3914618A1
(en)
|
2019-01-23 |
2021-12-01 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
EP3938390A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20210141998A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 제조 방법
|
KR20210141990A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
BR112021018441A2
(pt)
|
2019-03-18 |
2023-02-28 |
Janssen Biotech Inc |
Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
US20220324959A1
(en)
|
2019-06-03 |
2022-10-13 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
EP3976648A1
(en)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
WO2020247574A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Methods of purifying masked antibodies
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
EP4021479A2
(en)
|
2019-08-27 |
2022-07-06 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
WO2021046261A1
(en)
|
2019-09-05 |
2021-03-11 |
Poseida Therapeutics, Inc. |
Allogeneic cell compositions and methods of use
|
JP2023510121A
(ja)
|
2019-12-20 |
2023-03-13 |
ポセイダ セラピューティクス,インコーポレイティド |
抗Muc1組成物及び使用方法
|
KR20220149588A
(ko)
|
2020-03-04 |
2022-11-08 |
포세이다 테라퓨틱스, 인크. |
대사성 간 장애의 치료를 위한 조성물 및 방법
|
US20230121433A1
(en)
|
2020-03-11 |
2023-04-20 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
CA3174777A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions and methods for use in the treatment of cancer
|
EP4231999A1
(en)
|
2020-10-21 |
2023-08-30 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
WO2022182797A1
(en)
|
2021-02-23 |
2022-09-01 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
US20240189446A1
(en)
|
2021-02-23 |
2024-06-13 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2022187671A1
(en)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
KR20230156387A
(ko)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
EP4367137A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
CN117916260A
(zh)
|
2021-07-09 |
2024-04-19 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
WO2023060088A1
(en)
|
2021-10-04 |
2023-04-13 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
KR20240099249A
(ko)
|
2021-10-04 |
2024-06-28 |
포세이다 테라퓨틱스, 인크. |
트랜스포사제 및 이의 용도
|
KR20240099352A
(ko)
|
2021-10-29 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
AU2022396102A1
(en)
|
2021-11-23 |
2024-07-11 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024129459A1
(en)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Repairmen! of barrier dysfunction in esophagus
|